Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer.
Glenn J HannaJeffrey P GuenetteNicole G ChauCyrus M SayehliChristian WilhelmRobert MetcalfDeborah J WongMarcia BroseMohammad RazaqElisabeth Perez-RuizEzra E W CohenRahul AggarwalCatherine ScholzAntonio GualbertoAlan L HoPublished in: Cancer (2020)
Tipifarnib resulted in modest clinical activity with a promising disease control rate among patients with HRAS-mutant, R/M SGC who developed disease progression within the last 6 months.